Peptide YY Evidence Guide
Peptide YY has Phase 1 human data confirming its satiety effects, but intranasal and injectable formulations have faced tolerability challenges (nausea) that have stalled clinical development. The gut-brain satiety axis it engages is mechanistically important. At this stage, PYY is a useful research tool for understanding appetite regulation rather than a viable weight-loss protocol compound.
Our Take
Peptide YY has Phase 1 human data confirming its satiety effects, but intranasal and injectable formulations have faced tolerability challenges (nausea) that have stalled clinical development. The gut-brain satiety axis it engages is mechanistically important. At this stage, PYY is a useful research tool for understanding appetite regulation rather than a viable weight-loss protocol compound.
- Evidence context
- Gut-brain satiety axis research, appetite regulation mechanistic studies
- Evidence grade
- Level C
- Confidence
- Low
- Reference context
- Reported research reference: No established therapeutic protocol - Phase 1 doses vary by formulation and route
Benefits and Evidence
- Appetite Suppression: Level C, includes human evidence - Intravenous infusion of PYY3-36 reduced caloric intake by approximately 30% at ad libitum buffet meals in both lean and obese subjects in multiple controlled studies.
- Gastric Motility Reduction: Level B, includes human evidence - Slows gastric emptying and intestinal transit time, contributing to postprandial satiety through the ileal brake mechanism.
- Nausea: Level C, includes human evidence - Nausea is dose-limiting at higher infusion rates, restricting the therapeutic window for PYY-based treatments.
Side Effects and Warnings
- Nausea (dose-limiting)
- Abdominal discomfort
- Reduced gastric motility
- Mild headache
- Native peptide has very short half-life requiring continuous infusion
- Nausea is a significant dose-limiting side effect
- Modified analogs are still in early clinical development
- Interactions with other gut hormone therapeutics (GLP-1 agonists) not well characterized
Research Dosage References
- <strong>Intravenous infusion (research)</strong> - 0.8 pmol/kg/min - Continuous infusion during study periods - Research dosage producing physiological postprandial PYY levels. Higher doses cause nausea.
- <strong>Subcutaneous injection (investigational analogs)</strong> - Varies by analog - Once daily to once weekly (depending on formulation) - Modified PYY analogs with extended half-lives are in early clinical development. Native PYY3-36 has too short a half-life for practical subcutaneous use.
Mechanism of Action
PYY3-36 acts primarily through the neuropeptide Y2 receptor (Y2R), a Gi-coupled GPCR expressed on orexigenic NPY/AgRP neurons in the hypothalamic arcuate nucleus. Y2R is a presynaptic inhibitory autoreceptor - its activation by PYY3-36 inhibits NPY release from these neurons, thereby reducing the potent orexigenic (appetite-stimulating) drive of the NPY system. Simultaneously, reduction of NPY-mediated inhibition of adjacent anorexigenic POMC neurons results in increased alpha-MSH release and MC4R activation, promoting satiety. This dual mechanism - direct inhibition of appetite-stimulating neurons and indirect activation of satiety-promoting neurons - makes PYY a potent anorectic signal. PYY also acts peripherally to slow gastric emptying, reduce gastric acid secretion, and decrease intestinal motility (the "ileal brake"), which contributes to the sensation of fullness after meals. These effects are mediated through vagal afferent pathways and direct enteric nervous system signaling.
Legal Status
Not FDA approved. Investigational. Native PYY available as a research peptide.
Primary Sources
- Inhibition of food intake in obese subjects by peptide YY3-36. New England Journal of Medicine, 2003.
- Gut hormone PYY3-36 physiologically inhibits food intake. Nature, 2002.
Quick Answers
Where is the strongest evidence for Peptide YY?
Peptide YY has Phase 1 human data confirming its satiety effects, but intranasal and injectable formulations have faced tolerability challenges (nausea) that have stalled clinical development. The gut-brain satiety axis it engages is mechanistically important. At this stage, PYY is a useful research tool for understanding appetite regulation rather than a viable weight-loss protocol compound. Evidence context: Gut-brain satiety axis research, appetite regulation mechanistic studies.
What are the main side effects of Peptide YY?
Peptide YY side effects and warning signals include Nausea (dose-limiting), Abdominal discomfort, Reduced gastric motility, Mild headache, and Native peptide has very short half-life requiring continuous infusion.
What evidence level is Peptide YY?
Peptide YY is rated Level C; the listed research status is Phase 1.